Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doranidazole SCHEMBL8279382 | 1.00 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| Doranidazole SCHEMBL8279381 | 1.00 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| Doranidazole SCHEMBL7201581 | 1.00 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| Doranidazole SCHEMBL7208974 | 1.00 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| SCHEMBL9237087 | 0.91 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| SCHEMBL13627316 | 0.91 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| SCHEMBL9975773 | 0.91 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19TYMP | |
| SCHEMBL17706716 | 0.89 | KMT2A (0.43) | KMT2ALMNATHRBCYP2C19TYMP | |
| SCHEMBL17706714 | 0.89 | KMT2A (0.43) | KMT2ALMNATHRBCYP2C19TYMP | |
| SCHEMBL27791575 | 0.88 | KMT2A (0.49) | KMT2ALMNATHRBCYP2C19TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116241-B1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC (JP) | 2016-04-27 | — | — | EP | claimed |
| EP-2156832-B1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC (JP) | 2014-06-25 | — | — | EP | claimed |
| US-8541459-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2013-09-24 | — | — | US | claimed |
| US-8450356-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2013-05-28 | — | — | US | claimed |
| US-8420687-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2013-04-16 | — | — | US | claimed |
| US-8258166-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2012-09-04 | — | — | US | claimed |
| US-8258165-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2012-09-04 | — | — | US | claimed |
| US-8202898-B1 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2012-06-19 | — | — | US | claimed |
| US-20120136295-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2012-05-31 | — | — | US | claimed |
| US-20120136160-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2012-05-31 | — | — | US | claimed |
| US-20120130148-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2012-05-24 | — | — | US | claimed |
| US-20120129905-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2012-05-24 | — | — | US | claimed |
| US-20100130576-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2010-05-27 | — | — | US | claimed |
| US-20100076042-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2010-03-25 | — | — | US | claimed |
| EP-2156832-A1 | PHARMACEUTICAL COMPOSITION | Pola Pharma Inc. (JP) | 2010-02-24 | — | — | EP | claimed |
| EP-2116241-A1 | PHARMACEUTICAL COMPOSITION | Pola Pharma Inc. (JP) | 2009-11-11 | — | — | EP | claimed |
| US-5929104-A | Method for inducing apoptosis of cancer cell | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1999-07-27 | — | — | US | claimed |
| JP-9077667-A | — | — | None | — | — | JP | disclosed |
| US-5270330-A | 2-nitroimidazole derivative, production thereof, and radiosensitizer containing the same as active ingredient | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0513351-A1 | 2-NITROIMIDAZOLE DERIVATIVE, PRODUCTION THEREOF, AND RADIOSENSITIZER CONTAINING THE SAME AS ACTIVE INGREDIENT | POLA CHEMICAL INDUSTRIES INC (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076042-A1 | PHARMACEUTICAL COMPOSITION | MT-ND1, CYP2C19, KDM1A | KMT2A 700/4885LMNA 3680/4885THRB 4790/4885 |
| US-20120129905-A1 | PHARMACEUTICAL COMPOSITION | MT-ND1, CYP2C19, KDM1A | KMT2A 700/4885LMNA 3680/4885THRB 4790/4885 |
| US-20120136160-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, CYP2C18, CYP2D6 | KMT2A 3622/4885LMNA 3902/4885THRB 4567/4885 |
| US-20100130576-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, CYP2C18, CYP2D6 | KMT2A 3622/4885LMNA 3902/4885THRB 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.